Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | KDR positive |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| KDR positive | Advanced Solid Tumor | predicted - sensitive | Anti-VEGFR2 CAR CD8 lymphocytes | Preclinical | Actionable | In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes, displayed efficacy in inhibiting cell and tumor growth in a variety of solid tumor cell lines and mouse tumor models (PMID: 20978347). | 20978347 | |
| KDR positive | melanoma | predicted - sensitive | Anti-VEGFR2 CAR CD8 lymphocytes | Preclinical | Actionable | In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes increased survival of melanoma mouse models (PMID: 23633494). | 23633494 | |
| KDR positive | pancreatic cancer | sensitive | TAS-115 | Preclinical | Actionable | In a preclinical study, pancreatic islet endothelial cells were sensitive to TAS-115, resulting in decreased phosphorylation of Vegfr2, and inhibition of cell growth and angiogenesis in culture and mouse models (PMID: 24140932). | 24140932 | |
| KDR positive | Advanced Solid Tumor | predicted - sensitive | Tanibirumab | Phase I | Actionable | In a Phase I trial, Tanibirumab treatment demonstrated manageable toxicity and preliminary efficacy, resulted in increased circulating Kdr (Vegfr2), Vegf and Pigf, and stable disease in 61% (11/18) of patients with refractory solid tumors (PMID: 28391576; NCT01660360). | 28391576 |